Next-Generation Pipelines Set to Disrupt the Oncology and Vaccine Markets

With recent increased deal-making activity in the biotech sector, the second half of 2026 is poised to see a surge of pivotal clinical data in oncology and vaccines. The global Phase 3 Harmoni-3 trial of ivonescimab, a bispecific antibody co-developed by Summit Therapeutics and Akeso, is closely watched for its potential to demonstrate superiority over the current standard of care, Keytruda, and reshape the non-small cell lung cancer (NSCLC) market. Additionally, the Phase 3 (Interpath-001) trial of intismeran, a personalized cancer vaccine jointly researched by Moderna and Merck & Co., is a critical study to confirm the Phase 2 results that showed a 50% reduction in the risk of recurrence in surgically treated melanoma patients. Furthermore, the release of Phase 3 data for VAX-31, Vaxcyte's 31-valent pneumococcal vaccine, is expected to disrupt the dominance of Pfizer's Prevnar franchise, which currently generates $6 billion in annual revenue.

Innovative New Drugs Targeting Central Nervous System Disorders to be Evaluated for Commercial Potential

The central nervous system (CNS) field will see key clinical trial results for several promising new drugs targeting Alzheimer's disease psychosis (ADP) and treatment-resistant depression, generating significant market interest. Bristol Myers Squibb plans to announce Phase 3 (ADEPT-2) trial results for Cobenfy, Karuna Therapeutics' schizophrenia treatment acquired in late 2023 for $14 billion, to expand its indication to Alzheimer's disease psychosis. Given that initial sales of Cobenfy for schizophrenia have fallen short of market expectations, the success of its expansion into the Alzheimer's disease psychosis market, which affects up to half of the approximately 7 million Alzheimer's patients in the United States, will be crucial for its potential to become a blockbuster drug. Additionally, the Phase 3 results for COMP006, a psilocybin-based depression treatment developed by Compass Pathways, could demonstrate its potential as an innovative treatment option for mental health disorders and accelerate the commercialization timeline for psychedelic medicine.

Next-Generation Treatments for Autoimmune and Rare Skin/Muscle Diseases

In the area of skin and immune-related rare diseases, several innovative new drugs are expected to release late-stage clinical data to challenge existing standard treatments. Celldex Therapeutics will release data from the Phase 3 (Embarq-CSU1/2) trial of barzolvolimab, an antibody treatment that inhibits mast cells, for chronic spontaneous urticaria (CSU). This drug has shown faster onset and longer duration of action compared to Xolair, and if it can alleviate concerns about side effects, it could capture a significant share of the large market for immune-related diseases. BioGen will also announce the results of the Phase 3 (TOPAZ-1/2) trial of litifilimab in more than 1,100 patients with systemic lupus erythematosus (SLE), aiming to demonstrate its potential as a blockbuster candidate with annual sales exceeding $2 billion.

Competition for Dominance in Cardiovascular Disease and RNA Therapeutics Markets

Finally, in the fields of cardiovascular and genetic disease treatments, innovative new drugs utilizing RNA and gene editing technologies are competing for market share. Novartis plans to release Phase 3 (Harbor) trial results for del-desiran, an antibody-oligonucleotide conjugate (AOC) acquired from Avidity Biosciences in early 2026 for $12 billion, to confirm its potential as a treatment for Duchenne muscular dystrophy (DMD). Additionally, the Phase 3 (Cardio-TTRansform) trial results for eplontersen, co-developed by AstraZeneca and Ionis, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are also highly anticipated. These results will be a key indicator of whether the drug can penetrate the market currently dominated by Pfizer's Vyndamax, which generates over $6 billion in annual sales, and will likely determine market share in comparison to Alnylam's Amvuttra.